Created in 2004, and profitable since 2006, BMSystems is the first, and to date, the only company that succeeded to create validated in-silico heuristic models of complex human pathologies and physiological processes. As presented during the meeting, we presently offer to our clients or partners the possibility to generate new & pertinent hypotheses, stop in time existing programs and launch lower risks, novel therapeutics programs without being obliged to change their existing R&D/discovery processes. The short-term issue of the industry is not to change the development and R&D processes that work pretty well, but to focus its efforts on the right program!

For this reason, and because we often start as "B" plan, our clients and partners have more and more frequently incorporated measures that would secure their R&D and acquisitions programs, so that "B" plan could become the leading "A" plan.

As a result, we do not sell our technologies nor give access to them, but deliver the outputs in open formats. Our clients/partners are not dependent upon external proprietary technologies to maintain and update these new & pertinent hypotheses. We do not use their proprietary data to generate the first version of a CADI*™ model, and we limit data transfers to experimentations results only during the CADI model’s validation phase.

What we already did for ourselves: 4 patents, 2 therapeutic spin-offs, and for our clients/partners, we can do it with you. (do not hesitate to visit our website to download all our publications and patents).

If you are interested to learn more about our recent achievements and possible collaborations in the fields of neurodegenerative diseases, psychiatric and cognitive disorders, infectious diseases, biodefense, and cancer we shall be happy to talk with you or people of your organization.

We shall be participating to Bio Europe, October 31-November 2, 2011 in Dusseldorf.

Do not hesitate to contact us for more information.